


**Supplementary Figure 1. CCR2<sup>-/-</sup> mice are protected by MPLA.** C57BL6 WT and CCR2<sup>-/-</sup> mice were primed with MPLA or vehicle and infected with intravenous *S. aureus*. 3 days following infection, organs were harvested. *S. aureus* cfu recovered from A) lung, B) spleen, C) kidney. D) 4X immunohistochemical F4/80<sup>+</sup> staining from kidney and lung in WT vehicle, WT MPLA-primed, and CCR2<sup>-/-</sup> MPLA-primed mice. Data shown as mean +/- SEM. \*, p < .05 as determined by ANOVA with Tukey's post-hoc multiple comparison test

**A**



**Supplementary Figure 2. Metabolite enrichment of U-<sup>13</sup>C-glucose in MPLA-primed macrophages.** BMDMs were primed with MPLA and exposed to media where the only glucose source was U-<sup>13</sup>C-glucose for 24 hours. 24hr macrophages were exposed to MPLA throughout this time. BMDMs were then harvested and metabolites were assessed by GC-MS. A) Percent enrichment of each measured metabolite with the fractional number of glucose carbons incorporated. M = expected mass of metabolite. M1-M6= expected mass + 1-6, indicating the number of incorporated glucose carbons. Data shown as mean +/- SEM. \*, p < .05 as determined by ANOVA with Tukey's post-hoc multiple comparison test.